FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVie's Humira (adalimumab) Prescribing Information
Drugs.com,
/PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S.
/PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S.
Information contained on this page is provided by an independent third-party content provider.
Information contained on this page is provided by an independent third-party content provider.
Information contained on this page is provided by an independent third-party content provider.